Showing 4181-4190 of 8129 results for "".
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1]
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- ADORING Trials: Tapinarof Cream, 1% Effective in Patients with Skin of Colorhttps://practicaldermatology.com/news/adoring-trials-tapinarof-effective-in-patients-with-skin-of-color/2462266/In a patient population with diverse skin tones, tapinarof cream, 1% (VTAMA®, Dermavant) was shown to have significant efficacy in both adults and children as young as 2 years of age with atopic dermatitis (AD), according to new results presented at the 2024 American Academy of Dermatology Annual
- Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasishttps://practicaldermatology.com/news/thermo-fisher-scientific-launches-corevitas-clinical-registry-in-generalized-pustular-psoriasis/2462265/Thermo Fisher Scientific announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RW
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annu
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous